Vaccines effective against most SARS-CoV-2 variants

Two of the commonly used coronavirus vaccines provide protection against multiple variants of the virus that causes COVID-19, including the highly infectious Delta variant, a new Yale study has found.

The findings, published Oct. 11 in the journal Nature, also show at those infected with the virus prior to vaccination exhibit a more robust immune response to all variants than those who were uninfected and fully vaccinated.

The results come as an increase in so-called "breakthrough" infections caused by the Delta variant among vaccinated individuals continues to raise questions about whether the vaccines offer broad protection against newly arising variants.

According to the researchers, the Moderna and Pfizer-BioNTech vaccines do bolster the immune system’s response to infection.

"Vaccines induce high levels of antibodies against Delta and most variants," said Akiko Iwasaki, the Waldemar Von Zedtwitz Professor of Immunobiology and co-corresponding author of the paper. "And two shots are better than one."

In addition, the results suggest that booster shots can be effective in warding off SARS-CoV-2, the authors say.

For the study, a research team led by Iwasaki and two co-corresponding authors - Nathan Grubaugh, associate professor of epidemiology at Yale, and Saad Omer, director of the Yale Institute for Global Health - collected blood samples from 40 healthcare workers in the Yale New Haven Health System between November, 2020 and January, 2021 before they had received vaccinations. In the following weeks, they periodically took additional samples after the volunteers received their first and second doses of the Moderna or Pfizer-BioNTech mRNA vaccines.

The researchers then exposed the volunteers' blood samples to 16 different SARS-COV-2 variants, including the Delta variant, the most predominate strain circulating in the United States, and then measured antibody and T cell response to each of the variants. (None of the volunteers was exposed to the virus.)

The researchers found evidence of enhanced immune system response in all blood samples, although the strength of response varied by variant and by individual. The immune system response to the Delta variant in the blood of all volunteers was generally robust - and even stronger in samples collected after the individuals' second shots.

The breakthrough cases attributed to the Delta variant are unlikely to arise from a failure of vaccines, Iwasaki said. Rather, they likely stem from the extremely infectious nature of the Delta variant, which can overcome the immune defense, she said.

Other studies have also shown that vaccinated individuals tend to have less severe infections.

"The Delta variant is more infectious than earlier variants," Grubaugh added. "The high transmissibility of the variant, not its escape from our vaccine-induced immune response, best explains infections among the vaccinated."

The researchers also divided healthcare volunteers into two groups: those who had been infected by COVID-19 prior to vaccination and those who had not. The immune response of those infected prior to vaccination was more robust than for those who never been infected.

"Recovering from an initial infection is like getting a first vaccine shot," Iwasaki said.

A booster shot among those vaccinated could have a similar effect, increasing presence of antibodies and T cells that protect against infections, she said.

Yale's Carolina Lucas, Chantal Vogels, and Inci Yildirim are co-lead authors of the study.

Lucas C, Vogels CBF, Yildirim I, Rothman JE, Lu P, Monteiro V, Gelhausen JR, Campbell M, Silva J, Tabachikova A, Peña-Hernandez MA, Muenker MC, Breban MI, Fauver JR, Mohanty S, Huang J; Yale SARS-CoV-2 Genomic Surveillance Initiative, Shaw AC, Ko AI, Omer SB, Grubaugh ND, Iwasaki A.
Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity.
Nature. 2021 Oct 11. doi: 10.1038/s41586-021-04085-y

Most Popular Now

Pfizer to provide U.S. government with 10 million …

Pfizer Inc. (NYSE: PFE) today announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candid...

GSK and Vir Biotechnology announce United States g…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) announced US government contracts totalling approximately $1 billion[1] (USD) to purchase so...

Primary endpoint met in COMET-TAIL Phase III trial…

GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Vir) (Nasdaq: VIR) announced headline data from the randomised, multi-centre, open-label COMET-TAIL Phase...

Two billion doses of AstraZeneca’s COVID-19 vaccin…

AstraZeneca and its partners have released for supply two billion doses of their COVID-19 vaccine to more than 170 countries across every continent on the planet in the l...

Merck and Ridgeback's molnupiravir, an oral COVID-…

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Re...

Johnson & Johnson COVID-19 vaccine named one o…

The editors of Time announced that the Johnson & Johnson COVID-19 vaccine has been selected as one of Time's Best Inventions of 2021. The vaccine, for which Johnson & ...

New target for COVID-19 vaccines identified

Next generation vaccines for COVID-19 should aim to induce an immune response against 'replication proteins', essential for the very earliest stages of the viral cycle, c...

Repurposing a familiar drug for COVID-19

For the past year and a half, the COVID-19 pandemic has continued to engulf the globe, fueled in part by novel variants and the uneven distribution of vaccines. Every day...

Safety concerns raised for neuroblastoma candidate…

St. Jude Children's Research Hospital scientists looking for drugs to improve survival of children with high-risk neuroblastoma found a promising candidate in CX-5461. Th...

Pfizer and BioNTech receive expanded U.S. FDA emer…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. Food and Drug Administration (FDA) has expanded the emergency use authorization (EUA) of a ...

'Dancing molecules' successfully repair severe spi…

Northwestern University researchers have developed a new injectable therapy that harnesses “dancing molecules” to reverse paralysis and repair tissue after severe spinal ...

A target for potential cancer drugs may, in fact, …

In recent years, much scientific effort and funding has focused on developing drugs that target an enzyme with the unwieldy name of Src homology 2-containing protein tyro...